YD Bio Limited (YDES)
NASDAQ:YDES
Want to see YDES full AI Analyst Report?
Top Page
YD Bio Limited
(NASDAQ:YDES)
Select Model
Select Model
Rating:42Neutral
Price Target:
$2.50
Action:Reiterated
Date:06/24/26
The score is driven primarily by weak financial performance—widening losses, accelerating cash burn, and negative equity indicating funding and balance-sheet risk. Technicals add further pressure with a strong downtrend (below all key moving averages and negative MACD), only slightly tempered by near-oversold RSI/Stochastic readings. Valuation is also constrained by negative earnings (negative P/E) and no dividend data to offset risk.
Positive Factors
Low Reported Debt
Very low reported debt materially reduces refinancing and interest-rate risk, giving management structural flexibility. For a development-stage biotech, low leverage preserves capacity to raise equity or non-dilutive financing to fund trials and regulatory milestones without immediate interest burden.
Negative Factors
Negative Equity
A negative equity position signals accumulated losses and balance-sheet strain, which constrains financing options and heightens dilution risk. For a biotech, this structural weakness raises probability of future recapitalizations or creditor-driven remedies if cash needs persist.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Reported Debt
Very low reported debt materially reduces refinancing and interest-rate risk, giving management structural flexibility. For a development-stage biotech, low leverage preserves capacity to raise equity or non-dilutive financing to fund trials and regulatory milestones without immediate interest burden.
Read all positive factors
YD Bio Limited (YDES) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$182.64M
Dividend YieldN/A
Average Volume (3M)91.42K
Price to Earnings (P/E)―
Beta (1Y)0.33
Revenue GrowthN/A
EPS Growth14.61%
CountryUS
Employees4
SectorFinancial
Sector Strength70
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding70,789,260
10 Day Avg. Volume96,756
30 Day Avg. Volume91,419
Financial Highlights & Ratios
PEG Ratio1.29
Price to Book (P/B)-284.80
Price to Sales (P/S)1362.74
P/FCF Ratio-101.20
Enterprise Value/Market Cap0.94
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-57.76
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
YD Bio Limited Business Overview & Revenue Model
Company Description
Breeze Holdings Acquisition Corp. is a clinical-stage biopharmaceutical company based in Taipei, Taiwan. The firm concentrates its efforts on developing medical diagnostics for cancer prevention and creating exosome-based therapeutics, both of whi...
How the Company Makes Money
null...
YD Bio Limited Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
34
Negative
Cash Flow
16
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 596.82K | 510.36K | 350.13K | 0.00 | 0.00 |
| Gross Profit | 0.00 | -42.15K | 155.36K | 153.44K | 0.00 | 0.00 |
| EBITDA | -2.99M | -8.10M | -1.28M | 22.25K | 3.79M | 8.70M |
| Net Income | -2.97M | -8.31M | -1.41M | 13.56K | 3.79M | 8.70M |
Balance Sheet | ||||||
| Total Assets | 2.95M | 13.78M | 6.86M | 321.21K | 17.93M | 118.06M |
| Cash, Cash Equivalents and Short-Term Investments | 6.31K | 6.01M | 3.13M | 87.10K | 14.13K | 5.40K |
| Total Debt | 0.00 | 6.76K | 22.55K | 47.58K | 0.00 | 0.00 |
| Total Liabilities | 19.00M | 16.64M | 273.98K | 298.22K | 6.74M | 9.11M |
| Stockholders Equity | -16.05M | -2.86M | 6.59M | 22.99K | 11.20M | 108.96M |
Cash Flow | ||||||
| Free Cash Flow | -1.18M | -8.04M | -4.75M | -55.95K | -3.02M | -688.42K |
| Operating Cash Flow | -1.18M | -6.60M | -1.84M | -55.66K | -3.02M | -688.41K |
| Investing Cash Flow | 7.95M | -1.44M | -2.90M | -290.00 | 100.38M | -1.15M |
| Financing Cash Flow | -6.81M | 10.87M | 7.73M | 113.89K | -97.34M | 1.15M |
YD Bio Limited Technical Analysis
―
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For YDES, the sentiment is undefined. The current price of undefined is equal to the 20-day moving average (MA) of ―, equal to the 50-day MA of ―, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of ― indicates undefined momentum. The RSI at ― is undefined, neither overbought nor oversold. The STOCH value of ― is undefined, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a undefined sentiment for YDES.
YD Bio Limited Peers Comparison
UnderperformOutperform
Sector (68)
YDES
YD Bio Limited
2.63
-9.25
-77.85%
SCNI
Scinai Immunotherapeutics
0.27
-2.25
-89.21%
ADTX
Aditxt
0.04
-39,785.00
-100.00%
SPRC
SciSparc Ltd.
5.87
-54.58
-90.30%
CDT
CDT Equity
1.09
-488.91
-99.78%
VRAX
Virax Biolabs Group Ltd. Class A
0.13
-0.63
-82.63%
YD Bio Limited Corporate Events
YD Bio Posts Wider 2025 Loss as SPAC Deal Fuels R&D and U.S. Expansion
May 1, 2026
On April 30, 2026, YD Bio Limited reported its full-year 2025 results, highlighting a 17% rise in net revenue to about $597,000, driven by higher pharmaceutical sales such as Keytruda and new product launches, alongside a shift away from higher-pr...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.